Search
Alvotech SA
ALVOAdd to Watchlist
3.565USD
-0.015-0.42%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
1.11BMarket Cap
37.00P/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-0.42%
5 Days
-3.65%
1 Month
+10.71%
6 Months
-30.51%
Year to Date
-30.51%
1 Year
-60.69%
Key Figures
3.670Open
3.700High
334.37KVolume
37.00P/E TTM
17.77P/E Dynamic
--Dividend TTM
0.11%Turnover Ratio
3.580Prev. Close
3.550Low
719.92KTurnover
LossP/E Static
-3.94P/B
0.00%Div Yield TTM
2.06%ROA
11.85052wk High
0.70Volume Ratio
-231.86MNet Profit
312.15MShares
0.0964EPS TTM
0.22Beta
--ROE
3.03052wk Low
4.19%Amplitude
56.50%Gross Margin
1.11BMarket Cap
5.27Reward/Risk
3.67%Risk Rate
TradingKey Stock Score of Alvotech SA
Currency: USD Updated: 2026-07-01Key Insights
Alvotech SA's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 123 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 6.50.In the medium term, the stock price is expected to remain stable.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Alvotech SA's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Alvotech SA Highlights
StrengthsRisks
Alvotech SA is a biotechnology company. The Company is focused on the development and manufacture of biosimilar medicines for patients globally. It is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). It has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 530.64% year-on-year.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Overvalued
The company’s latest PE is 37.15, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 19.07M shares, decreasing 10.94% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 191.88K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 2.28.
Analyst Rating
Based on
5
analysts
Buy
Current Rating
6.500
Target Price
+76.15%
Upside Space
Alvotech SA News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Alvotech SA Info
Alvotech SA is a biotechnology company. The Company is focused on the development and manufacture of biosimilar medicines for patients globally. It is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). It has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.
Ticker SymbolALVO
CompanyAlvotech SA
CEOWessman (Robert)
Websitehttps://www.alvotech.com/
Related Instruments
+1.33%
+2.83%
+5.32%
+3.44%
+2.26%
+3.06%
+3.01%
+2.95%
+3.47%
+1.82%
+4.20%
+1.56%
+3.97%
+3.16%
+2.05%
0.00%
+3.30%
+3.10%
+0.25%
+4.50%Popular Instruments
52766.900
+512.600 (+0.98%)
29255.100
-544.200 (-1.83%)
7464.300
-11.200 (-0.15%)
14763.000
-592.000 (-3.85%)
67909.000
-1576.000 (-2.27%)
6348.100
+72.700 (+1.16%)
68.354
+0.386 (+0.57%)
308.310
+13.930 (+4.73%)
193.510
-4.070 (-2.06%)
4117.530
+86.760 (+2.15%)
FAQs
What is the current price of Alvotech SA (ALVO)?
The current price of Alvotech SA (ALVO) is 3.58.
What is the symbol of Alvotech SA?
The ticker symbol of Alvotech SA is ALVO.
What is the 52-week high of Alvotech SA?
The 52-week high of Alvotech SA is 11.85.
What is the 52-week low of Alvotech SA?
The 52-week low of Alvotech SA is 3.03.
What is the market capitalization of Alvotech SA?
The market capitalization of Alvotech SA is 1.21B.
Is Alvotech SA (ALVO) currently rated as Buy, Hold, or Sell?
According to analysts, Alvotech SA (ALVO) has an overall rating of Buy, with a price target of 6.50.
What is the Earnings Per Share (EPS TTM) of Alvotech SA (ALVO)?
The Earnings Per Share (EPS TTM) of Alvotech SA (ALVO) is 0.10.